A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α, Toll‐like receptors, and ischemic tissue damage. RIP1 has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Nicholas S., Kshirsagar, Smita, Mohanan, Vishnu, Ramakrishnan, Vidya, Di Nucci, Flavia, Ma, Ling, Mao, Jialin, Ding, Hao, Klabunde, Sha, Vucic, Domagoj, Pan, Lin, Lekkerkerker, Annemarie N., Chen, Yuan, Rothenberg, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582670/
https://www.ncbi.nlm.nih.gov/pubmed/37596814
http://dx.doi.org/10.1111/cts.13607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582670/
https://www.ncbi.nlm.nih.gov/pubmed/37596814
http://dx.doi.org/10.1111/cts.13607

Ejemplares similares